Danaher Corporation (DHR)

Today, Danaher’s portfolio is concentrated on areas that support biological research, drug development, bioprocessing, clinical diagnostics, and laboratory workflows. Its life sciences businesses provide tools used in areas such as cell analysis, genomics, proteomics, microscopy, filtration, and biomanufacturing. These products are important to academic research, applied science, and the development and production of biologic medicines. In diagnostics, Danaher’s businesses offer systems and tests used by hospitals and laboratories to detect disease, guide treatment decisions, and improve patient care.

The company is known for the Danaher Business System, a management approach influenced by lean manufacturing and continuous improvement principles. This operating culture is central to how Danaher integrates acquisitions, improves productivity, and allocates capital across its portfolio. The company has also actively refined its structure through divestitures and spin-offs, including the separation of its environmental and applied solutions businesses into Veralto in 2023.

Danaher operates in markets shaped by scientific innovation, healthcare demand, regulatory standards, and long-term investment in biopharmaceutical research and diagnostics. Its recurring revenue from consumables and services, combined with specialised instruments and deep customer relationships, helps distinguish it from broader industrial conglomerates.